☆ 4.7 Letter

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059

BLOOD (2017)

Journal

BLOOD

Volume 129, Issue 20, Pages 2808-2810

Publisher

AMER SOC HEMATOLOGY

DOI: 10.1182/blood-2017-02-765115

Keywords

Funding

Cancer Research UK Leicester Centre
Leicester Experimental Cancer Medicine Centre
Gilead Sciences, Inc.
MRC [MC_U132670597] Funding Source: UKRI
Medical Research Council [MC_U132670597] Funding Source: researchfish

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059

Journal

BLOOD

Publisher

AMER SOC HEMATOLOGY

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059

Journal

BLOOD

Publisher

AMER SOC HEMATOLOGY

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper